Should biologic agents be stopped before surgery for inflammatory bowel disease?

Despite the widespread use of anti-TNF agents for inflammatory bowel disease (IBD), the need for surgical intervention remains high. As a result, many IBD patients undergoing surgery have recently been exposed to biologic agents. There is considerable controversy regarding the potential adverse effects of biologic agents on surgical outcomes in IBD patients undergoing major colorectal surgery with studies showing conflicting results. There appears to be discordance in the systemic bioavailability of anti-TNF-α in patients with Crohn’s disease (CD) versus ulcerative colitis, with greater systemic absorption in CD. In patients with CD, preoperative serum anti-TNF-α levels may help guide timing of surgery as patients with elevated serum anti-TNF-α levels appear to be at higher risk for complications. In patients with ulcerative colitis there is likely no need for stopping biologic agents before surgery as there is poor systemic bioavailability of the drug in a majority of patients.

[1]  S. Targan,et al.  The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. , 2015, Annals of surgery.

[2]  U. Ali,et al.  Impact of Preoperative Immunosuppressive Agents on Postoperative Outcomes in Crohn’s Disease , 2014, Diseases of the colon and rectum.

[3]  D. Fan,et al.  Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. , 2014, International journal of surgery.

[4]  O. Zmora,et al.  Anti‐tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.

[5]  Zhiping Yang,et al.  Meta‐analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery , 2012, Alimentary pharmacology & therapeutics.

[6]  W. Sandborn,et al.  Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  M. Silverberg,et al.  Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease , 2012, Gut.

[8]  J. Becker,et al.  Preoperative Infliximab is not Associated with an Increased Risk of Short-Term Postoperative Complications After Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis , 2011, Journal of Gastrointestinal Surgery.

[9]  S. Finlayson,et al.  Trends in Surgery for Crohn's Disease in the Era of Infliximab , 2008, Annals of Surgery.

[10]  Malfertheiner,et al.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. , 2010, Inflammatory bowel diseases.

[11]  P. Rutgeerts,et al.  Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis , 2009, Inflammatory bowel diseases.

[12]  M. Esteve,et al.  Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  J. Korzenik,et al.  Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications , 2008, Journal of Gastrointestinal Surgery.

[14]  J. Church,et al.  Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients , 2008, Journal of Gastrointestinal Surgery.

[15]  F. Remzi,et al.  Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy , 2008, Diseases of the colon and rectum.

[16]  G. Lichtenstein Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis? , 2008 .

[17]  W. Harmsen,et al.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. , 2007, Journal of the American College of Surgeons.

[18]  M. Regueiro,et al.  Infliximab for Hospitalized Patients With Severe Ulcerative Colitis , 2006, Journal of clinical gastroenterology.

[19]  W. Harmsen,et al.  Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy , 2004, American Journal of Gastroenterology.

[20]  P. Rutgeerts,et al.  The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study , 2004, Alimentary pharmacology & therapeutics.

[21]  L. Moldawer,et al.  Inhibition of tumor necrosis factor‐α attenuates wound breaking strength in rats , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[22]  T. Ulich,et al.  Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. , 1987, Journal of immunology.

[23]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[24]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.